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Abstract
Background: Exome sequencing, which allows the global analysis of protein coding sequences in the human
genome, has become an effective and affordable approach to detecting causative genetic mutations in diseases.
Currently, there are several commercial human exome capture platforms; however, the relative performances of
these have not been characterized sufficiently to know which is best for a particular study.
Results: We comprehensively compared three platforms: NimbleGen’s Sequence Capture Array and SeqCap EZ,
and Agilent’s SureSelect. We assessed their performance in a variety of ways, including number of genes covered
and capture efficacy. Differences that may impact on the choice of platform were that Agilent SureSelect covered
approximately 1,100 more genes, while NimbleGen provided better flanking sequence capture. Although all three
platforms achieved similar capture specificity of targeted regions, the NimbleGen platforms showed better
uniformity of coverage and greater genotype sensitivity at 30- to 100-fold sequencing depth. All three platforms
showed similar power in exome SNP calling, including medically relevant SNPs. Compared with genotyping and
whole-genome sequencing data, the three platforms achieved a similar accuracy of genotype assignment and SNP
detection. Importantly, all three platforms showed similar levels of reproducibility, GC bias and reference allele bias.
Conclusions: We demonstrate key differences between the three platforms, particularly advantages of solutions
over array capture and the importance of a large gene target set.
Background
Identifying genetic alterations underlying both rare and
common diseases, and also other phenotypic variation,
is of particular biological and medical relevance. Even
after a decade’s effort by the genetics research commu-
nity since the completion of the first human genome
sequences [1,2], most genetic mutations underlying
human diseases remain undiscovered. For example, the
causative mutations for more than half of human rare
diseases [3], the genetic architecture of most common
diseases [4,5] and the roles of somatic mutations in
most cancers [6] have yet to be characterized. Whole
genome re-sequencing can potentially identify these
uncharacterized mutations, and in the past few years
great strides have been made in this regard with mas-
sively parallel DNA sequencing technologies that can be
applied to the whole genome [7-10]. However, the cost
of these technologies remains too high for them to be
used as a standard method. Recent integration of tar-
geted exome capture with massively parallel sequencing
to selectively re-sequence the best-understood functional
parts of the human genome - comprising less than 2%
of protein-coding sequences - provides an effective and
affordable alternative to identify some of these causative
genetic changes.
Several platforms for human exome capture for mas-
sively parallel sequencing have been developed and mar-
keted to date [11-14]. In principle, these platforms fall
into three classes: DNA-chip-based capture [11,12],
DNA-probe-based solution hybridization [14], and
RNA-probe-based solution hybridization [13]. These
platforms have resulted in great success in pioneering
studies hunting for variants causing rare human diseases
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[11,15-21], and have also been adopted in efforts
towards deciphering human common disease and cancer
genomes. Yet questions remain about which of these
platforms is best for a given application. For example,
how many human genes are targeted by each approach
and how even is their coverage? How do capture effi-
cacy, technological reproducibility and biases among the
different platforms compare? How much input DNA is
required and how convenient is each experimentally?
How does the cost-effectiveness compare? And what is
the power and accuracy of SNP calling, especially for
medically important rare SNPs? Up till now, publicly
accessible explorations of methodology have been lim-
ited to proof-of-concept studies [11,13,14,22], reviews
[23,24], or comparisons carried out on only a subset of
genes rather than at the whole-genome level [25].
To provide the community with a more solid means
to determine the best platform for their experimental
needs, we have performed a comprehensive compari-
son of three commercial human exome capture plat-
forms: NimbleGen’s Sequence Capture Array (Human
Exome 2.1 M Array, Roche-NimbleGen), NimbleGen’s
SeqCap EZ (v1.0, Roche-NimbleGen), and Agilent’s
SureSelect (Human All Exon Kits, Agilent). Each of the
three platforms represents one of the classes of exome
capture technology currently available. To assess per-
formance with regard to key parameters, including
reproducibility, we conducted deep exome capture
sequencing for each platform with two technical dupli-
cates (>30× and >60× coverage) using DNA derived
from a cell line from a previously sequenced Asian
individual [26]. Other key performance parameters
characterized here include the genes targeted, the effi-
cacy of exome capture (including specificity, uniformity
and sensitivity), technological biases, and the power
and accuracy of exome capture data for subsequent
SNP calling. Our findings provide comprehensive
insights into the performance of these platforms that
will be informative for scientists who use them in
searching for human disease genes.
Results
Human exome capture with the three platforms
We chose platforms that allowed a comparison of the
three different methods currently in use for exome cap-
ture. The platforms are based on a chip-hybrid method
(NimbleGen Sequence Capture Array) or a solution-
hybridization method (NimbleGen SeqCap EZ) with a
common set of DNA probes, and a solution hybridiza-
tion method with RNA probes (Agilent SureSelect). The
test DNA sample was from a cell line derived from the
individual used in the YanHuang whole-genome sequen-
cing analysis [26], allowing comparison with the existing
high-coverage genome sequence.
We sought to comprehensively compare the perfor-
mance of the three exome capture platforms using the
best protocols and experimental design for each. We
therefore optimized the standard library construction
protocols for all three platforms (see Materials and
methods): we minimized the input DNA to 10 μg, 3 μg,
and 3 μg for Sequence Capture Array, SeqCap EZ and
SureSelect, respectively, and set pre-capture PCR to four
cycles and post-capture PCR to ten cycles for all three
platforms. We included duplicates for each technique to
ensure the reliability and assess the reproducibility of
data production. We thus constructed a total of six
libraries for the three platforms and used the HiSeq2000
to initially produce >30-fold coverage of unique mapped
paired-end 90-bp reads (PE90) for each library. We
further sequenced one of the two replicates for each
platform to >60-fold coverage to obtain a combined
coverage of approximately 100-fold for the purpose of
discovering the impact of sequence depth on genotype
calling for each of the platforms.
Targeted genes and coverage
One intrinsic feature of exome capture is its capacity for
simultaneous interrogation of multiple targets depending
directly on the genes targeted by the capture probes. We
first compared the targeted genes and their coverage
among the three platforms. As the two platforms (array
and EZ) developed by NimbleGen shared a common set
of targets, we only needed to compare the Agilent and
one NimbleGen platform. We annotated protein-coding
genes using a merged dataset of 21,326 genes from the
CCDS database (release of 27 March 2009), refGen
(release of 21 April 2009) and EnsemblGen databases
(release 54), and microRNA genes using 719 genes from
the human microRNA database (version 13.0). We also
included the 200-bp most-flanking regions from both
ends of the targeted sequences: typically, 200-bp flank-
ing regions are co-captured with capture libraries con-
structed from 200- to 250-bp fragments.
The two target sets were 34.1 Mb (NimbleGen) and
37.6 Mb (Agilent) in size, and shared 30 Mb of targets
in common, leaving 4.1 Mb specific to NimbleGen and
7.6 Mb specific to Agilent (Table S1 in Additional file
1). Correspondingly, although both target sets contain
similar percentages of functional elements (exomic,
>71%; intronic, >24%; and others, <5%), Agilent covered
approximately 1,000 more protein-coding genes and
approximately 100 more microRNA genes (17,199 pro-
tein coding genes, 80.6% of the database total; 658
microRNA genes, 91.4%) than NimbleGen (16,188 pro-
tein-coding genes, 75.9%; 550 microRNA genes, 76.5%)
(Table S2 in Additional file 1). Of those protein-coding
genes, 15,883 overlapped between NimbleGen and Agi-
lent, while 305 were unique to NimbleGen and 1,316
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were unique to Agilent. Further analyses showed no
over-representation of any class of annotated disease
genes in the NimbleGen- or Agilent-specific genes
(Table S3 in Additional file 1). In addition, both
included roughly 1.6 transcripts per gene, a value con-
sistent with the average number of transcripts per gene
in the RefSeq database. The results indicated that the
majority of known human genes and their splice alterna-
tives were well accounted for in both capture probe
designs.
We assessed the coverage of the protein-coding
sequences (CDs) by the two platforms, and again, Agi-
lent-targeted regions showed much better coverage
(72.0% of targeted genes with >95% CDs, and 78.5%
with >90% CDs) than NimbleGen’s (46.1% of targeted
genes with >95% CDs, and 61.5% with >90% CDs) (Fig-
ure S1 in Additional file 2). However, when including
the flanking regions, the coverage was much more
improved for NimbleGen (74.2% targeted genes with
>95% CDs and 76.0% with >90% CDs) than for Agilent
(82.0% targeted genes with >95% CDs and 83.0% with
>90% CDs) (Figure S1 in Additional file 2). This reduced
the gap in CD coverage rate (from >17% to <8%)
between the two analysis sets and indicated a more
important role of flanking region capture for
NimbleGen.
To obtain more detailed information about the target
coverage of these two systems, we looked specifically at
their ability to interrogate human disease genes using
four known data sets (see below). Of the 5,231 unique
genes collected from the Online Mendelian Inheritance
in Man database (OMIM; release of 10 March 2011),
Human Gene Mutation Database (HGMD; Professional
2009.2), and Genome-Wide Association Study (GWAS;
release of 3 March 2011) and Cancer Genome Project
(CGP; release of 1 December 2010) databases, Agilent
targeted 4,871 with 86% of genes having >95% of CDs
covered, in comparison with NimbleGen’s 4,642 genes
with 83% of genes and >95% of CDs covered (Figure S2
in Additional file 2). Thus, for the current pool of
disease genes, both could interrogate most known genes,
especially those linked to rare diseases, for which 85% of
known causative mutations occur in CDs. This makes
both capture methods especially attractive for rare dis-
ease gene identification and analysis.
Exome capture specificity
To assess the extent of exome enrichment, we compared
the capture specificity of the three platforms, which was
defined as the proportion of reads mapping to target
regions. For the two replicates of each platform, we
obtained a total of 26 to 80 million filtered reads (2.2 to
7.2 Gb; Table 1), roughly corresponding to >30- and
>60-fold coverage of the targeted regions. We mapped
these reads to the human genome (hg18) using the
strategy described in the Materials and methods.
Although the overall proportion of filtered reads that
could be mapped (78.8 to 86.4%) or uniquely mapped
(69.2 to 82.8%) to the human genome differed between
the six replicates, the proportions of reads mapped
uniquely to targeted regions were more comparable
(54.2 to 58.1%) among the three platforms (Table 1).
We also found the percentages of uniquely mapping
reads were further improved (by up to 12%) for the two
NimbleGen platforms by the inclusion of 200-bp flank-
ing regions in the analyses (for the Agilent platform,
this was only 2%). Thus, the final percentage of usable
reads was 66.6% for the two NimbleGen platforms but
was <60% for the Agilent platform. These results indi-
cated that there is a general comparability of capture
specificity for targeted regions among the three plat-
forms if the mapping method does not include the
flanking region sequences. However, under mapping
procedures where researchers do include this informa-
tion, the NimbleGen platforms perform better.
Uniformity of coverage
The uniformity of sequence depth over targeted regions
determines the genotype sensitivity at any given
sequence depth in exome capture. The more uniform
Table 1 Capture specificity of the three human exome capture platforms
Filtered Mapped to genome Uniquely mapped to
genome
Uniquely mapped to
TR
Uniquely mapped to
TFR
Replicatea Reads
(M)
Read
length
Bases
(Mb)
Percent of
reads
Bases
(Mb)
Percent of
reads
Bases
(Mb)
Percent of
reads
Bases
(Mb)
Percent of
reads
Bases
(MB)
NA_r1 37 PE90 3,352 85.2 2,793 81.4 2,682 53.5 1,437 63.1 2,064
NA_r2 58 PE90 5,210 79.3 4,115 76.0 3,944 56.4 2,370 67.9 3,481
NS_r1 31 PE90 2,781 86.4 2,402 82.3 2,287 54.2 1,192 67.7 1,860
NS_r2 80 PE90 7,230 85.9 6,163 82.8 5,964 55.0 3,175 67.6 4,787
AS_r1 26 PE90 2,220 84.4 1,868 74.4 1,645 58.1 1,146 60.1 1,332
AS_r2 66 PE90 5,720 78.8 4,496 69.2 3,950 54.6 2,776 56.4 3,225
aAS, Agilent solution; NA, NimbleGen array; NS, NimbleGen solution; r1 and r2 are two replicate experiments for each platform. TFR, targeted and flanking
regions; TR, targeted regions.
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the sequencing depth on the targeted region is for a
platform, the lower the depth of sequencing that is
required to obtain a desired genotype sensitivity. To
assess this important quality metric, we selected and
analyzed a similar number of reads (approximately 25
million filtered reads, on average approximately 30-fold
coverage) from each of the six replicates (Table 2). We
found that although all three platforms showed high
coverage of their own targeted regions at low sequen-
cing depth (98 to 99% with >1×), the Agilent platform
showed more bias towards very low and very high cov-
erage (21% with <10×, 20% with >50×) than the two
NimbleGen platforms (<15% with <10×, 7% with >50×).
As a result, the two NimbleGen platforms had 10 to
15% more targeted regions (70 to 74%) within 10× to
50× coverage than the Agilent platform (59%). This
observation was further supported when we looked at
the normalized single base sequencing depth distribu-
tion (Figure 1). The curve of the two NimbleGen plat-
forms showed less skew to low and high coverage
depths, and more evenness around the mean coverage
(approximately 30×), than that of the Agilent platform;
that is, the NimbleGen Array showed the best evenness.
In addition, the two NimbleGen platforms also showed
better uniformity of coverage in flanking regions (Table
2), which is consistent with their better efficiency of
capture seen when including the flanking region
sequences (Figure S3 in Additional file 2). Thus, the two
NimbleGen platforms had a better overall uniformity of
sequencing depth than Agilent, which would be
expected to impact the relative genotype sensitivity
when considering all targets.
Genotype sensitivity
Although the coverage of >99% of each targeted region
of more than one-fold using all data sets an upper
boundary for exome capture sensitivity for each repli-
cate, only a proportion of these sites gained high-quality
genotype assignments. To characterize this issue, we
compared the genotype sensitivity in the 30× data sets
(Figure 2a) using the criterion of >10-fold coverage and
Phred-like quality >30. In these analyses, all three plat-
forms showed very high genotype sensitivity (>77%);
but, in comparison, the two NimbleGen platforms
showed 6 to 8% higher (>83%) genotype sensitivity than
the Agilent platform (approximately 77%), which is con-
sistent with their better uniformity in coverage depth.
To obtain a more comprehensive insight, we further
analyzed genotype sensitivity at other sequencing depths
(Figure 2b) by randomly sampling from the combined
sequencing data of the two replicates for each platform.
Overall, the genotype sensitivity improved for all three
platforms in a similar way as sequencing depth
increased, and reached as high as >92% at approximately
100-fold coverage. The genotype sensitivity of the two
NimbleGen platforms was often higher than the Agilent
platform at a given sequencing depth. For example, gen-
otype sensitivity was between 72% and 91% for the Nim-
bleGen platforms at the usual sequencing depth of 20-
to 50-fold, while it was 64 to 85% for the Agilent plat-
form. Of interest, the curves of the two NimbleGen plat-
forms nearly overlapped when sequence coverage depth
was >30-fold. This indicates that these two platforms,
which share a common set of DNA capture probes,
have good inter-comparability.
We also analyzed genotype sensitivity at flanking
regions; better NimbleGen results further emphasized
the importance of the flanking regions for NimbleGen.
From the above, we conclude that all three platforms
had high genotype calling sensitivity at >30-fold cover-
age (>77%), with NimbleGen platforms showing slightly
better performance.
Reproducibility
Technical reproducibility reflects the consistency of
performance of each exome capture platform. Using
the replicates for each of the three exome capture plat-
forms, we determined the level of reproducibility
within each platform. In considering inter-platform
comparability as well, our evaluation focused on the
set of targets that were shared between all three plat-
forms (totaling 182,259 consensus coding sequences
Table 2 Uniformity of depth by three human exome capture platforms
Filtered Mean coverage (×) Coverage depth (percent of bases in TR) Coverage depth (percent of bases in FR)
Replicatea Reads (M) Bases (Mb) On TR On FR 0× 1× to 10× 10× to 50 × >50× 0× 1× to 10× 10× to 50× >50×
NA-r1 25.5 2,280 30.8 9.3 1.3 12.3 69.8 16.6 6.8 56.2 36.8 0.2
NA-r2 27.1 2,421 30.0 8.5 1.0 11.2 73.8 14.1 7.4 53.1 33.1 0.1
NS-r1 26.1 2,338 30.1 10.8 1.7 13.0 69.7 15.6 6.1 53.1 39.5 1.3
NS-r2 25.5 2,289 30.3 9.9 1.5 13.6 68.5 16.3 6.7 56.4 35.8 1.0
AS-r1 25.7 2,222 32.7 3.5 2.1 18.6 59.5 19.8 46.8 42.7 10.1 0.4
AS-r2 25.1 2,175 32.5 3.4 2.2 19.0 59.0 19.8 47.3 42.4 9.9 0.4
For the analyses, a set of data that has 30-fold coverage on targeted regions was randomly selected for each of the six replicates. aAS, Agilent solution; NA,
NimbleGen array; NS, NimbleGen solution; r1 and r2 are two replicate experiments for each platform. FR, flanking region; TR, targeted region.
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(CCDSs) covering 25,392,537 bp). This accounted for
70.1% and 66.1% of sensitivity in the NimbleGen and
Agilent targeted regions, respectively. Using the
approximately 30× data set, we analyzed the correla-
tion of both coverage rate and mean depth on the
CCDSs between any two of the six replicates (Figure
3). Each platform showed high intra-platform reprodu-
cibility (correlation coefficient at >0.65 for coverage
rate and >0.90 for depth). The lower correlation coeffi-
cient for coverage rate (0.65 to 0.78) than for mean
depth (0.90 to 0.96) was not surprising since the two
correlations reflect different aspects of the data - that
is, the quantitative sequencing depth and qualitative
sequence coverage. For the inter-platform comparison,
the two NimbleGen platforms showed higher correla-
tion for both coverage rate and mean depth than the
Agilent platform. This is consistent with the fact that
the two platforms share a common set of DNA capture
probes. These results together indicate generally high
and comparable technical reproducibility of the three
methods.
GC bias and reference allele bias
Base composition has been shown to have a systematic
effect on capture performance [13]. To explore this
effect, we plotted mean sequencing depth against GC
content. All three platforms showed biases against extre-
mely low GC content (<20%) and high GC content
(>75%), and the best coverage for GC content of 40 to
60% (Figure S4 in Additional file 2). However, we also
observed a better coverage for the NimbleGen array
platform, which had a better coverage of low GC con-
tent sequences without reduced coverage of the best-
covered GC content. Thus, extreme GC content still
poses a challenge for exome capture, but the chip-hybri-
dization method (NimbleGen array platform) would
likely be a better choice for targeted capture of genomic
regions with lower GC content.
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The allelic status of the probe sequences could also
influence allelic capture efficiency at heterozygous sites,
especially in situations where there are a large number
of novel alleles being interrogated by exome capture.
This occurs because the probes match the reference
sequence and might capture perfectly matching library
fragments better. To explore the impact of allelic status
on the different platforms, we compared the ratio of
reference allele depth to total depth for heterozygous
sites in each exome capture with that in YanHuang
whole-genome shotgun sequencing (WGSS). All three
platforms showed consistent and significant biases
towards the reference allele in capture (Figure S5 in
Additional file 2), whereas WGSS did not have this bias.
These results emphasize the need to account for the
effect of reference allele bias in exome sequencing of
tumors, in which acquired somatic mutations at any fre-
quency may occur.
Non-covered sequences
Even at 100-fold sequencing depth, a small proportion
of the target region was still not covered by each plat-
form. To gain insight into this issue, we analyzed the
base composition of these missed sequences. In total,
97,654 to 190,318 sequences (0.29 to 0.56% of two tar-
geted regions) were not covered at all by the combined
full sets of data for each platform. Of these sequences,
19,803 (10 to 20% of the non-covered sequences) over-
lapped in all three platforms, and 71,257 (33% and 70%
of the non-covered sequences) overlapped between the
two NimbleGen platforms. The GC content was >72%
for Agilent, >80% for NimbleGen Array, >79% for Nim-
bleGen EZ, and 76% for all shared sequences. Thus, at
very high sequencing depth (approximately 100×), the
non-covered sequences for all three platforms were
biased towards extremely high GC content.
SNP detection
Given that exome capture is used primarily to identify
genetic variants, we compared the SNP detection power
among the three platforms. To do so, we called SNPs in
the targeted regions together with 200-bp flanking
sequence at high quality genotype-assigned sites in each
of the approximately 30× data sets, and annotated them
using the combined gene set used in the target annota-
tion. Each platform detected roughly 25,000 to 40,000
SNPs, of which the largest group was from intronic
regions, followed by synonymous SNPs and then non-
synonymous SNPs, and finally by other categories
(Table S4 in Additional file 1). The over-representation
of intronic SNPs was more marked for the two Nimble-
Gen platforms, where it provided over 10,000 more
SNPs (35,000 to 40,000 in all) than the Agilent platform
(25,000). Given the use of the same DNA and the simi-
lar proportion of intronic regions between the Nimble-
Gen and Agilent platforms, this seems to be largely
associated with the increased efficiency of capture by
the NimbleGen platforms, especially in the flanking
sequences. However, for synonymous and non-synon-
ymous SNPs, which together represent the most
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Figure 2 Genotype sensitivity. (a) Genotype sensitivity of six replicates at 30× sequencing depth. (b) Genotype sensitivity as a function of
sequencing depth. For the analyses, subsets of reads from two combined replicate datasets for each platform were randomly extracted at
different average depths. NA, NS and AS represent NimbleGen Sequence Capture Arrays, NimbleGen SeqCap EZ and Agilent SureSelect,
respectively, while r1 and r2 are two replicate experiments for each platform.
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functionally important groups, the Agilent and Nimble-
Gen data showed substantial overlap and nearly similar
levels of SNPs per gene to whole genome re-sequencing
of the same individual. Thus, the three platforms could
interrogate a similar high level of SNPs within protein-
coding sequences in their targeted genes, which harbor
changes that are most likely to have a functional impact.
Accuracy of genotype and SNP calling
To assess their accuracy, we compared the genotypes
and SNPs from each replicate (30× data) of the three
platforms with those from Illumina 1 M beadchip geno-
typing and WGSS (about 36×) from the YanHuang pro-
ject [26]. For better data comparability, we also derived
genotypes for the WGSS using the same software and
criteria as for the exome capture (see Materials and
methods).
In comparison with the Illumina 1 M beadchip geno-
typing, which includes 1,040,000 successfully typed sites,
each replicate showed approximately 39,000 to approxi-
mately 51,000 overlapping sites depending on the plat-
form, and showed an overall genotype concordance of
>99.81% for these sites (Table 3). In addition, each plat-
form also achieved a similar high concordance rate with
those variant sites found by chip genotyping, with
>99.51% for all the SNP sites, and >99.56% for non-
reference homozygous sites, and of particular note, even
>99.48% for heterozygous sites, the genotypes of which
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Figure 3 Correlation of sequencing depth and coverage rate on consensus targeted CCDSs. The graph shows pair-wise Pearson
correlation coefficients for both sequencing depth (top-left triangle) and coverage rate (bottom-right triangle) based on the 182,259 CCDSs
targeted by both Agilent and NimbleGen. NA, NS and AS represent NimbleGen Sequence Capture Arrays, NimbleGen SeqCap EZ and Agilent
SureSelect, respectively, while r1 and r2 are two replicate experiments for each platform.
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are more difficult to assign than homozygous sites (Table
3). Relatively, the concordance of chip genotyping to the
variant sites in each exome capture was also high, with
>99.81% for all the SNP sites, and >99.88% for non-refer-
ence homozygous sites, and >99.71% for heterozygous
sites (Table 3). These comparisons give a maximum esti-
mate of both the false negative rate and false positive rate
of <0.52% for the three exome captures.
In contrast, the two NimbleGen and Agilent datasets
overlapped at 48,000,000 sites (with 83.8% sensitivity in
targets) and 34,500,000 sites (with 76.2% sensitivity in
targets) with WGSS genotypes, respectively. The sub-
stantially higher overlap of NimbleGen was attributed to
its greater intronic content. This time, each exome cap-
ture platform showed a concordance of >99.999% for all
overlapping sites, but >99.20% for all SNP sites, >99.92%
for the homozygous non-reference sites and >97.90% for
the heterozygous sites found in WGSS (Table 3). In
comparison, the relative concordance of WGSS to the
variant sites called in each exome capture was >97.97%
for all SNP sites, >99.75% for the homozygous non-
reference sites, and in particular was reduced to
>96.65% for the heterozygous sites (Table 3), which is
still acceptable. Note that for the heterozygous sites,
compared to NimbleGen, Agilent showed approximately
1% reduction in concordance. In these analyses, cell-line
DNA (approximately 40 generations) derived from lym-
phoblasts was sequenced using a read length of 90 bp,
while for WGSS reads of 36 bp in length were generated
from whole blood DNA. Thus, cell-line mutations, and
errors due to increased sequencing length (errors accu-
mulate with sequencing length) in the study may
account for part of the decrease in concordance. Based
on these results, the general false positive and false
negative rate of each exome capture platform for SNP
detection was <3.4% and <1.0%, respectively.
Taken together, these results indicate that although
slight differences could be observed, accuracy was both
high and comparable among the three platforms.
Detection of medically interesting rare mutations
To further explore the power of the three exome cap-
ture platforms at identifying disease-causing rare muta-
tions, we modeled the performance of each with the
SNP set present in HGMD (Professional 2009.2) but
absent from the 1000 Genomes Project database (BGI
in-house data) (Table 4). Of the 39,906 mutations repre-
senting 1,931 diseases genes, both Agilent and Nimble-
Gen targeted >95.8% sites, and showed >93.4% sites
with at least 1× coverage and genotype sensitivity of
>79% sites (>10× coverage and >Q30) at 30× sequencing
depth. But in comparison, Agilent targeted more sites
(98.5% compared to 95.8%), and correspondingly
showed approximately 1.5% more covered sites (>1×
coverage; 95.1% compared to 93.4%) than NimbleGen.
In contrast, NimbleGen (the best performance was with
NimbleGen Array Capture) showed 1.4% more genotype
sensitivity (80.4% compared to 79%), and 3.6% less low
quality coverage sites or uncovered sites (15.2% com-
pared to 18.8%) than Agilent. The number of known
potentially disease-causing SNPs detected ranged from
14 to 19 (Table 3). These observations are consistent
with the larger targeted gene set of Agilent, and the
higher capture efficiency of NimbleGen. Thus, the ana-
lyses demonstrated the very high power of the three
exome capture platforms for identifying medically inter-
esting rare mutations.
Performance on common targeted regions
Hitherto, most of the comparisons have been based
directly on the current versions of the three platforms,
which may not reflect only the intrinsic differences in
performance among the three methods, but also the dif-
ferences in content. To address this issue, we compared
key performance parameters on the approximately 30
Mb of targeted regions in common (83.3 Mb with flank-
ing sequences; Table S1 in Additional file 1). For specifi-
city, we found that each replicate of the three platforms
showed a somewhat reduced unique mapping rate of
Table 3 Concordance of genotypes and SNPs
Concordance with 1 M bead genotyping data Concordance with WGSS data
Replicatea All
genotypes
SNPs
in 1
M
chip
SNPs in
exome
capture
Homs
in 1 M
chip
Homs
in
exome
capture
Hets
in 1
M
chip
Hets in
exome
capture
All
genotypes
SNPs
in
WGSS
SNPs in
exome
capture
Homs
in
WGSS
Homs
in
exome
capture
Hets
in
WGSS
Hets in
exome
capture
NA-r1 99.846 99.641 99.826 99.649 99.987 99.633 99.687 99.999 99.216 98.636 99.951 99.868 98.683 97.750
NA-r2 99.854 99.670 99.835 99.708 99.975 99.637 99.714 99.999 99.264 98.616 99.943 99.850 98.768 97.724
NS-r1 99.854 99.679 99.819 99.682 99.951 99.676 99.707 99.998 99.211 98.396 99.974 99.747 98.657 97.426
NS-r2 99.849 99.660 99.841 99.684 99.987 99.640 99.716 99.999 99.197 98.706 99.979 99.752 98.629 97.949
AS-r1 99.816 99.526 99.823 99.571 99.948 99.486 99.712 99.998 98.783 98.021 99.917 99.824 97.945 96.703
AS-r2 99.815 99.514 99.805 99.556 99.880 99.477 99.738 99.998 98.762 97.972 99.927 99.771 97.893 96.645
For each replicate, the 30-fold data set used for Table 2 analyses was also used for the analyses. aAS, Agilent solution; NA, NimbleGen array; NS, NimbleGen
solution; r1 and r2 are two replicate experiments for each platform. Hets, heterozygotes; Homs, homozygotes.
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>44% filtered reads to the common targeted regions,
and that the two NimbleGen platforms achieved, on
average, a 12% higher unique mapping rate than the
Agilent platform when including the 200-bp flanking
sequences in the analyses (Table S5 Additional file 1).
This result is consistent with the initial analyses above.
For uniformity and sensitivity, we also found that each
platform showed very similar performance to that above,
and that the two NimbleGen platforms performed better
than the Agilent one (Table S5 in Additional file 1). For
example, at a sequencing depth of 30×, NimbleGen had, on
average, approximately 6% higher genotype sensitivity than
Agilent (85% compared to 79%). For SNP detection, the
detection level of each SNP category in each platform,
including the greater detection of intronic SNPs (and thus
the total SNP number) by the NimbleGen platforms
(>13,000 more SNPs than Agilent, >35,000 compared to
approximately 22,000), was also similar to the analyses
above (Table S4 in Additional file 1); but in comparison,
despite general inter-comparability, the two NimbleGen
platforms detected approximately 400 more coding SNPs
(12,400 compared to 12,000) in the common targeted
regions while the Agilent platform detected approximately
900 more coding SNPs elsewhere (13,500 compared to
12,600) (Table S4 in Additional file 1). This difference
could be explained by the fact that NimbleGen had a better
capture efficiency while Agilent targeted an approximately
4-Mb larger region and correspondingly 1,000 more genes.
Finally, for the accuracy of SNP detection and geno-
types, we also observed similar false positive and false
negative rates for each platform at 30× coverage (Table
S6 in Additional file 1) to that in whole dataset in com-
parison with the data from array genotyping and WGSS.
Thus, we conclude that each platform was highly consis-
tent in performance in the common targeted region
analyses here compared with the analyses of the entire
content above, which is not surprising given the high
overlap (Agilent, 30 Mb/34.1 Mb ≈ 80%; NimbleGen, 30
Mb/40 Mb ≈ 88%).
Discussion
In this study, we present a comprehensive comparison
of three widely adopted human whole-exome capture
platforms from two manufacturers. Since the three plat-
forms, in principle, represent the three classes of exome
capture technologies currently available, data on their
performances likely also reflect the intrinsic power and
limitations of exome capture as a technology.
For the current versions of the three platforms, the
number of targeted genes and their CD coverage rate
are important considerations for human genetic studies.
Although most well-annotated human genes (>76%)
were targeted by all three platforms, Agilent sought to
target a larger set of genes (approximately 1,000 more
protein-coding genes and approximately 100 more
microRNA genes) and thus provided a better coverage
of protein-coding sequences. In contrast, NimbleGen
emphasized a more important role for flanking regions
in capture probe design, and, in practice, had a greater
number of genes with a high rate of CD coverage (Fig-
ure S6 in Additional file 2) due to better capture
efficiency.
Exome capture efficiency is another important factor
for comparison of capture platforms. In our hands, we
observed that the two NimbleGen platforms showed
better capture efficiency than the Agilent platform. Spe-
cifically, the two NimbleGen platforms showed approxi-
mately 10% higher capture specificity with the expanded
targeted regions (66.6% compared to 58.3%), better uni-
formity of coverage, and 3 to 7% more sensitivity in gen-
otype assignment (83 to 95% compared to 76 to 92%
over the range 30× to 100× coverage of targeted
regions). Thus, a lower sequencing depth was required
for NimbleGen platforms for a given genotype sensitivity
on targeted regions, which can impact experimental
cost.
The ability to identify SNPs in protein-coding
sequences, especially those medically interesting rare
mutations, which ultimately measures the power of
exome sequencing, was another important considera-
tion. Despite general inter-comparability (12,500 to
13,500 SNPs), we found that, at the same sequencing
depth (30×), NimbleGen detected a more complete set
of SNPs (approximately 400 more SNPs) than Agilent
for the common targeted coding sequences due to better
exome capture efficiency, but the Agilent platform could
Table 4 Power for identifying disease-causing rare mutations
NA-r1 NA-r2 NS-r1 NS-r2 AS-r1 AS-r2
High quality genotype assigned sites 32,139 32,674 31,750 31,923 31,685 31,353
Reference genotypes 32,124 32,658 31,732 31,909 31,666 31,335
SNPs 15 16 18 14 19 18
Low quality genotype assigned sites 6,064 5,529 6,453 6,280 7,349 7,681
Uncovered 1,703 1,703 1,703 1,703 872 872
For each replicate, the 30-fold data set used for Tables 2 and 3 analyses was also used for this analysis. AS, Agilent solution; NA, NimbleGen array; NS, NimbleGen
solution; r1 and r2 are two replicate experiments for each platform.
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detect more SNPs (approximately 900 SNPs) in total
number due to its larger number of targeted genes.
Similarly, for identifying medically interesting rare muta-
tions, we found in model analyses that all three plat-
forms not only showed similar high power at 30×
sequencing depth in interrogating known HGMD muta-
tions filtered to remove 1000 Genomes Project variants
present in the general population, but the small differ-
ences reflected the general features of each platform
(Agilent could target 1.8% more, and cover 1.5% more
mutation sites, but NimbleGen showed 1.4% more
mutations with high quality genotype assignment).
Input DNA amount, the convenience of conducting
experiments and the cost of reagents will also be impor-
tant considerations. Especially, the amount of DNA
required for each method itself will impact cost as well
as the ease of carrying out experiments, and is a major
consideration for precious biological samples with lim-
ited availability. In these senses, the two solution hybrid
platforms, Agilent and NimbleGen EZ, showed great
advantages over the chip hybridization platform. These
two solution-based platforms require smaller amounts
of input DNA (approximately 3 μg) and no specialized
equipment. In addition, reagent costs for these two plat-
forms are lower when more than ten samples are being
studied, and could possibly be further reduced with the
introduction of sample pooling prior to the capture
possess.
For performance aspects, such as the accuracy of SNP
detection, GC bias and reference allele bias, and repro-
ducibility, we did not observe great differences among
the three platforms.
Taken together, our results here demonstrate that
although the three platforms showed general compar-
ability of performance, the two solution hybrid platforms
would be the leading choice for most studies, especially
those using large numbers of samples. In comparing
these two, the Agilent platform showed a larger set of
targets, targeting a more comprehensive set of human
protein-coding genes and providing more complete cov-
erage of their CDs, while the NimbleGen platform had
better capture efficiency and could provide a higher pro-
portion of CDs with high quality genotype assignments
(thus higher completeness of SNP detection), and
required lower sequence coverage because of its greater
evenness. Thus, a choice between the two platforms is
surprisingly difficult: both are highly effective and the
number of targeted genes, their CD coverage, genotype
sensitivity and sequencing amount/cost required must
be balanced. The larger number of genes targeted by
Agilent provides an overall advantage in the versions
used here, but it is important to point out that both
NimbleGen and Agilent are making great progress in
target design. For example, in the latest (July 2011)
versions, both target sets have been expanded (Nimble-
Gen EZv.20 to 44 Mb, Agilent to 50 Mb), and currently
cover more than 90% of annotated human genes (Table
S7 in Additional file 1).
Conclusions
We demonstrate here a systematic evaluation of the per-
formance of the current versions of three human whole-
exome capture platforms. The data reported here will
make it easier for researchers to more carefully assess
the type of exome capture technology that will work
best for their experimental goals and costs, and allow
them to improve their own experimental design to take
advantage or reduce the limitations of the available plat-
form types.
Materials and methods
Genomic DNA and kit preparation
Genomic DNA was extracted from a lymphoblastoid cell
line of YanHuang [26] using proteinase K and phenol/
chloroform [27] and further subjected to RNase treatment.
DNA sample quality and quantity were initially character-
ized by gel electrophoresis and nano-drop measurement,
and further quantified using the Quant-iT dsDNA HS
Assay kit (0.2 to 100 ng; Invitrogen, Q32854, Carlsbad,
CA, USA). NimbleGen Sequence Capture Array (Human
Exome 2.1 M Array) and SeqCap EZ (v1.0) kits, and Agi-
lent SureSelect kits (Human All Exon Kits) were pur-
chased from their respective manufacturer.
Exome capture library preparation
Prior to library construction, we optimized the manufac-
turers’ standard protocols for our sequencing pipeline.
Major parameters for optimization included input DNA
quantity, fragmentation size, number of PCR cycles and
indexing system. As a result, we adopted the following
protocol.
Input DNA quantities of 10 μg, 3 μg and 3 μg were
used for NimbleGen Sequence Capture Array, Nimble-
Gen SeqCap EZ and Agilent SureSelect library prepara-
tion, respectively. The DNAs were fragmented to 200 to
250 bp in size, followed by end-repair, A-tailing and
BGI paired-end index adapter ligation, following the
Illumina DNA library preparation protocol described
elsewhere [28]. Four cycles of pre-capture amplification
were then conducted with Platinum Pfx DNA polymer-
ase (Invitrogen) under the PCR conditions: 2 minutes at
94°C; four cycles of 10 s at 94°C, 30 s at 62°C, and 30 s
at 72°C; then 300 s at 72°C. PCR products were further
analyzed using a Bioanalyzer (Agilent, Santa Clara, CA,
USA), and quantified by Qubit BR measurement (Invi-
trogen) before performing exome capture.
Exome capture was performed with the PCR products
following each of the three manufacturers’ standard
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protocols. Then, ten cycles of post-capture amplification
were conducted using Platinum Pfx DNA polymerase
(Invitrogen) under slightly modified PCR conditions
compared to pre-capture amplification (2 minutes at 94°
C; 10 cycles of 10 s at 94°C, 30 s at 58°C, and 30 s at
72°C; then 300 s at 72°C). Final libraries were validated
by Bioanalyzer analysis (Agilent) and quantitative PCR,
in preparation for massively parallel sequencing.
Sequencing and pre-mapping data process
Sequencing of each library was done on an Illumina
HiSeq2000 as paired-end 90-bp reads (PE90) after
indexing individual libraries and pooling them in pairs.
Each library was initially sequenced to a depth providing
an approximately 30-fold mapped coverage on targeted
regions, and then one of the two replicates was further
chosen from each of the three platforms to sequence to
>60-fold coverage on targeted regions. Raw image files
were processed by the Illumina pipeline (version 1.3.4)
for base calling and to generate a raw read set. Adapter
contamination and reads of low quality (more than four
‘N’ nucleotides) were identified and removed before
mapping.
Mapping, genotype and SNP calling
SOAP (v2.21) [29] was used to align the reads to the
NCBI human genome reference assembly (build 36.3)
with parameters set to ‘-a -b -D -o -u -t -l 35 -n 4 -r 1
-2 -v 2 -s 40’. These settings provided the best mapping
rate by giving highest priority to paired-end and then
lower priority to unpaired single-end matches. SOAPsnp
[30] (v1.03) was used to call consensus genotypes with
the parameters ‘-i -d -o -r 0.00005 -e 0.0001 -t -s -2 -u
-M -L -T’, where ‘-T’ used the targeted and flanking
regions. As our sample is from a male, we added the
parameter ‘-m’ for the sex chromosomes. Then SNPs
were extracted from the consensus genotype file, and
those with sequencing depth <10, quality <30, copy
number of a nearby region >2, or other SNPs within 5
bp were filtered out to get high-confidence calls.
Data accessibility
All data described here are being deposited to the NCBI
Sequence Read Archive [SRA:035389].
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